Endpoint Health

Endpoint Health's Antithrombin III for sepsis successfully completes Phase II trials with compelling efficacy and safety data, leading to a lucrative partnership with a major pharmaceutical company or an early acquisition at a valuation of $675M+, driven by the strong clinical evidence and the potential of its AI-driven precision medicine platform.

The company makes steady, albeit slower, progress in clinical trials, securing additional funding rounds at a modest step-up in valuation. It maintains its competitive position in precision sepsis therapies and AI in critical care, leading to a potential exit at around $180M, providing a limited return for common shareholders after accounting for liquidation preferences.

Clinical trials for Antithrombin III face significant setbacks or fail to meet primary endpoints, or the company struggles to secure follow-on funding due to market conditions or increased competition from incumbents like Prenosis (with its FDA-authorized AI diagnostic for sepsis). This leads to a down round or an acquisition at a distressed valuation of $22.5M or less, resulting in a near-total loss for common equity holders due to the substantial liquidation preferences.